Antimicrobial peptide PL-18 for treating vaginal infections

Overview

ProteLight Biopharma introduces PL-18, an innovative antimicrobial peptide designed to treat Vulvovaginal Candidiasis (VVC) and manage Recurrent VVC. The unique mechanism of action of PL-18 provides broad-spectrum activity against various pathogens, making it a promising alternative to traditional antibiotics. This solution aims to offer effective treatment with fewer side effects and a reduced risk of resistance, addressing a critical need in managing recurrent vaginal infections.

Technical specifications

Key features:

• Broad-spectrum antimicrobial activity against a wide range of pathogens
• Unique mechanism of action that reduces the risk of resistance development
• Potential for fewer side effects compared to traditional antibiotics

This peptide is particularly aimed at patients suffering from Recurrent VVC, providing a more sustainable and effective therapeutic option.

Technology readiness level

PL-18 has successfully completed phase Ib clinical trials in China and is advancing to phase II. ProteLight is actively seeking global and regional partners to further clinical development and commercialization efforts.